https://www.medscape.com/viewarticle/973869 Welcome to this video commentary about the long-term use of antithyroid drugs in the management of Graves disease. My name is Angela Leung. I'm an adult endocrinologist at the University of California in Los Angeles and the Veterans Affairs Greater Los Angeles Healthcare System.

I'm pleased to moderate this discussion today, and we have two esteemed guests with us. The first is Dr David Cooper. He is a professor of medicine and radiology at the Johns Hopkins University School of Medicine. He's the director of the thyroid clinic there, an internationally known expert for his work in thyroid research, and an esteemed educator and clinician. He's also one of the co-authors of the American Thyroid Association 2016 hyperthyroidism and thyrotoxicosis guideline.

We also have Dr Whitney Goldner, who is a professor of medicine in the Division of Diabetes, Endocrinology, and Metabolism in the Department of Medicine at the University of Nebraska College of Medicine and the University of Nebraska Medical Center. She is the medical director of the Thyroid and Endocrine Tumor Program there, and she is active in the Endocrine Society and the American Thyroid Association. Her clinical and research interests are in thyroid disease, thyroid nodules, and thyroid cancer.